via Johns Hopkins University School of Medicine
Johns Hopkins Medicine researchers have developed a color-coded test that quickly signals whether newly developed nanoparticles — ultra small compartments designed to ferry medicines, vaccines and other therapies — deliver their cargo into target cells.
Historically, nanoparticles have a very low delivery rate to the cytosol, the inside compartment of cells, releasing only about 1%–2% of their contents. The new testing tool, engineered specifically to test nanoparticles, could advance the search for next-generation biological medicines. The technology builds upon nanoparticles currently used against cancer and eye disease, and in vaccines for viruses including SARS-CoV-2, the virus that causes COVID-19.
The researchers report details of the tool, tested in mouse cells grown in the laboratory and in living mice, in the Jan. 5 issue of Science Advances.
“Many of the current assessment tools for nanoparticles only test whether a nanoparticle reaches a cell, not if the therapy can successfully escape the degradative environment of the endosome to reach inside the cytosol of the cell, which is where the medicine needs to be located for performance,” says Jordan Green, Ph.D., professor of biomedical engineering at the Johns Hopkins University School of Medicine. The new tool was created to track location and nanoparticle release, he said.
Previous research has estimated that only about 1%–2% of nanoparticles “eaten” by cells are able to escape the cellular compartments that trap them to avoid being digested or “spit back out.” In addition to the properties of its cargo, a nanoparticle’s chemical properties determine whether it is accepted by a cell and able to evade its cellular defenses.
To surmount such obstacles to final delivery, Green and his team designed a screening tool that assesses hundreds of nanoparticle formulations on their ability to not just reach a cell, but also how efficiently the nanoparticle can escape with its cargo to reach a cell’s interior.
The test uses mouse cells grown in the laboratory that are genetically engineered to carry a florescent marker called Gal8-mRuby, which shines orange-red when a cellular envelope that engulfs a nanoparticle opens, releasing its cargo into the cell.
Images of the process are then analyzed by a computer program that quickly tracks the nanoparticle location using red fluorescent light and quantifies how effective the nanoparticles are at being released into the cell by assessing the amount of orange-red fluorescent light. , with detailed information about the uptake of the nanoparticles and the delivery of their cargo.
In experiments in mice, Green and his team administered biodegradable nanoparticles carrying mRNA that encoded a gene called luciferase, which makes cells glow. The researchers then tracked whether the mouse cells accepted the gene and began expressing it — lighting up target cells like a lightning bug.
Green’s team found that the top-performing nanoparticles in the cellular tests had a high positive correlation to nanoparticle gene delivery performance in living mice, showing the nanoparticle assay is a good predictor of successful cargo delivery.
In further mouse studies, the researchers discovered that different chemical group combinations in the polymer-based nanoparticles led the nanoparticles to target different tissue types. By analyzing how the particles behaved in the mouse’s body, the researchers found that polymer chemical properties could direct the nanoparticle gene therapy to specific target cells, such as endothelial cells in the lungs or B cells in the spleen.
“By fine-tuning small chemical changes, we can steer a nanoparticle to specific tissues and even specific cells,” said Green. “This would allow us to develop more precisely delivered therapies, which could improve both efficacy and safety.”
Nanoparticle delivery of biological drugs is a growing field, particularly for gene therapies and vaccines.
More from: Johns Hopkins University School of Medicine
The Latest on: Nanoparticle drug delivery
- Nanoscale drug delivery system treats tumors by phoneon January 24, 2022 at 2:06 am
- Nanomedicine and COVID-19on January 22, 2022 at 2:45 am
Many strategies have been cultivated to use nanoparticles for COVID-19 treatment and drug delivery. Besides directly targeting SARS-CoV-2, nanoparticles can be used as immunomodulatory agents to ...
- Nanoparticles Put To the Test: No Glow, No-Goon January 20, 2022 at 7:02 am
These and other classes of nanoparticles aren't new technologies; chemists had developed similar drug delivery systems as far back as the 1960s. One of the main barriers holding nanoparticles back as ...
- Global Novel Drug Delivery Systems (NDDS) Market to Reach US$28.1 Billion by the Year 2026on January 20, 2022 at 3:35 am
Currently, the pharmaceutical industry is preparing for widespread adoption of nanoparticles, which represents a crucial element in advanced nanotechnology-enabled delivery systems. Amid the COVID-19 ...
- Global Novel Drug Delivery Systems (NDDS) Market to Reach US$28.1 Billion by the Year 2026on January 20, 2022 at 3:30 am
The rising uptake of nanotechnology and its various concepts including nanocarriers in novel drug delivery mechanisms is driving growth in the Nanoparticles segment. The use of nanoparticles in ...
- 'Waltzing' Nanoparticles Target Medication Deliveryon January 18, 2022 at 4:00 pm
Some of the latest research in this field comes out of Indiana University (IU), where researchers have discovered that drug-delivering nanoparticles can be made to “dance” so as to attach to targets ...
- PLGA-rhodamine from PolySciTech used in research on dexamethasone nanoparticle-based deliveryon January 18, 2022 at 10:59 am
Dexamethasone is an important anti-inflammatory compound used to treat arthritis. However its delivery and localization to the joint site remains poor.
- Nanoparticles Improve Immunosuppression, Could Boost Diabetes Treatmenton January 18, 2022 at 4:00 am
A nanocarrier delivery system re-engineered the immunosuppressive mechanism of the drug Rapamycin by changing the cell types that are targeted.
- Queen’s University Belfast: New drug delivery could significantly improve treatment outcomes for localised prostate canceron January 14, 2022 at 10:53 pm
The treatment can make cancerous cells up to 30% more receptive to radiotherapy while simultaneously reducing adverse side effects that limit quality of life. Radiotherapy is extensively used to treat ...
- Polymeric Nanoparticles and the Future of Gene Delivery Methodson January 14, 2022 at 2:21 am
This article will uncover the natural disposition of polymeric nanoparticles for function in biological activities such as targeting submandibular salivary glands. A major challenge within drug ...
via Bing News
The Latest on: Nanoparticle drug delivery
via Google News